Securities code: 002382 securities abbreviation: Blue Sail Medical Co.Ltd(002382) Announcement No.: 2022-008 bond Code: 128108 bond abbreviation: lanfan convertible bond
Blue Sail Medical Co.Ltd(002382)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance:
□ loss □ turning loss into profit □ rising in the same direction √ falling in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 900 million yuan – 130 million yuan profit: 1758477300 yuan net profit of shareholders decreased by 48.82% – 26.07% over the same period last year
Net profit after deducting non recurring profit and loss: 0-300 million yuan; Profit: 1741.8266 million yuan; decrease over the same period of last year: 100.00% – 82.78%
Basic earnings per share: 0.80 yuan / share – 1.30 yuan / share earnings: 1.82 yuan / share
2、 Communication with accounting firms
The financial data related to the 2021 annual performance forecast has not been audited by certified public accountants, but the company has pre communicated with the annual report audit accounting firm on matters related to the performance forecast, and there is no significant difference between the company and the accounting firm in the 2021 annual performance forecast.
3、 Explanation of performance change reasons
1. During the reporting period, the overall performance of CB cardio holdings II Limited (hereinafter referred to as “CBCH II”, please refer to the announcement on internal restructuring issued by the company on October 27, 2021) after internal restructuring decreased significantly. Among them, due to the repeated impact of China’s centralized procurement and foreign epidemics officially implemented from January 1, 2021, the increase of stent product sales failed to make up for the decline of price, and other coronary artery products have not been listed or in large quantities, resulting in a sharp decline in coronary artery business performance; The European market development of heart valve business is still in its infancy, and the first valve product in China has not been listed, resulting in limited performance growth of valve business; At the same time, the company continues to increase R & D and clinical investment in valve and coronary artery products; The above factors jointly led to the conversion of cardio cerebrovascular business division from profit to loss in 2021. In addition, the performance in 2021 is also superimposed with the impairment of capitalized development expenditure (mainly due to the impact of the epidemic, the impairment caused by the loss of the commercial value of some invested clinical registration projects caused by changes in the market situation), internal restructuring and equity incentive expenses, resulting in a loss of about 600-800 million yuan for CBCH II in 2021 (this data does not include the impact of goodwill impairment).
2. Based on the future cash flow forecast of CBCH II asset group at the acquisition time point, the company judges that CBCH II93 was acquired in the early stage The goodwill formed by 37% of the equity has signs of impairment. Based on the work results of the intermediary at this stage, it is proposed to withdraw an impairment provision of about 1.5-1.8 billion yuan for this part of goodwill. The final amount of goodwill impairment must be determined by the formal report issued by the audit institution and evaluation institution with the qualification to engage in Securities and futures related business hired by the company after audit and evaluation. 3. Since the second quarter of 2021, the selling price of health protection gloves has shown a significant downward trend, while the price of raw materials continues to fluctuate significantly. Under its comprehensive effect, the net profit contributed by the company’s health protection products in the whole year is expected to be about 2.2-2.5 billion yuan (this data does not include the impact of goodwill impairment and performance compensation).
4. According to the profit forecast compensation agreement on CB cardioholdings II Limited signed with Zibo lanfan Investment Co., Ltd. (hereinafter referred to as “lanfan investment”) and Li Bing Yung, Thomas Kenneth Graham and Wang Dan during the company’s major asset restructuring, According to the profit forecast compensation agreement on CB cardio holdings V Limited signed with Beijing Xinyu Investment Center (limited partnership) (hereinafter referred to as “Beijing Xinyu”), the target company CB cardio holdings II Limited held the 15th meeting of the 5th board of directors and the 14th meeting of the 5th board of supervisors on May 17, 2021 because it failed to complete the performance commitment in 2020, The 2020 annual general meeting of shareholders was held on June 8, 2021, and the proposal on the performance compensation scheme for the subject matter of major asset restructuring was reviewed and approved. The Company repurchased and cancelled 23361227 shares of the company held by lanfan investment and 24787109 shares of the company held by Beijing Xinyu at a total price of 1 yuan. Lanfan investment and Beijing Xinyu returned 317.71 dividends corresponding to the compensation shares at the same time
Li Bing Yung, Thomas Kenneth Graham and Wang Dan compensated the company with us $1613200, US $128800 and US $96600 in cash respectively. The total amount of the above performance compensation and compensation shares is 1.096 billion yuan, which has been implemented in June 2021. It is included in the financial assets measured at fair value and whose changes are included in the current profit and loss, which belongs to non recurring profit and loss items.
4、 Other relevant instructions
1. This performance forecast is the result of the preliminary estimation of the company’s financial department. The specific financial data shall be subject to the 2021 annual report officially disclosed by the company.
2. The information disclosure media designated by the company are China Securities News, Shanghai Securities News, securities times, securities daily and http://www.cn.info.com.cn, All information of the company is subject to the information disclosed in the above designated media. Please pay attention to the investment risks.
It is hereby announced.
Blue Sail Medical Co.Ltd(002382) board of directors
January 29, 2002
